CD147蛋白在前列腺癌中的表达及临床意义  

Expression and Clinical Significance of CD 147 Protein in Human Prostate Cancer

作　　者：蔡崇岳 伍彩云 杨宇峰 李宋荣 史向民 莫仰骐 郑志涛 

机构地区：[1]广东省东莞市第三人民医院泌尿外科,广东东莞523326

出　　处：《医学临床研究》2015年第11期2088-2090,共3页Journal of Clinical Research

基　　金：广东省医学科研基金（项目编号B2013433）

摘　　要：【目的】研究前列腺癌及前列腺增生组织中CD147蛋白的表达及其临床意义。【方法】采用免疫组化S‐P法检测56例前列腺癌组织及22例前列腺增生组织中CD147蛋白的表达情况，分析其与前列腺癌临床生物学特性的相关性。【结果】观察组CD147蛋白阳性率为643．％显著高于对照组的91．％，差异具有统计学意义（ P ＜00．1）。不同年龄段患者CD147蛋白的阳性表达无显著性差异（ P ＞00．5），不同 T N M 分期及病理分级 Gleason评分CD147蛋白的阳性表达有显著性差异（ P ＜00．5），各级别组CD147蛋白阳性表达率差异有统计学意义（ P ＜00．5）。【结论】前列腺癌组织中CD147高表达，并与其病理分期及临床分期有关。CD147有可能成为判断前列腺癌侵袭力的重要指标，阻断CD147的表达可能成为治疗前列腺肿瘤的新靶点。Objective]To investigate the expression and clinical significance of CD147 protein in human prostate cancer and benign prostatic hyperplasia tissues .[Methods]The immunohistochemical S‐P method was used to detect the expression of CD147 protein in 56 patients of prostate cancer tissues and 22 patients of be‐nign prostatic hyperplasia tissues so as To analyze the correlation between CD 147 protein and the clinical bio‐logical characteristics of prostate cancer .[Results]The positive rate of CD147 protein in the observation group was 9 1.% ,which was significantly higher than that in the control group ,the difference was statistically sig‐nificant （ P 〈0 0.1） .There was no significant difference in CD147 protein expression in different age groups （ P 〉0 0.5） .The positive expression of CD147 protein in different stages of Gleason staging and pathological grading was significantly different （ P 〈0 0.5） ,The positive expression rate of CD147 protein in each grade group was statistically significant （ P 〈0 0.5） .[Conclusions] The high expression of CD147 in prostate cancer tissues is related to its pathological stage and clinical stage .CD147 has the potential to be an important indica‐tor to judge the invasion of prostate cancer ,and to block the expression of CD147 may become a new target for the treatment of prostate cancer .

关 键 词：抗原  CD147/生物合成 前列腺肿瘤/病理学 肿瘤侵润 肿瘤分期 

分 类 号：R737.25[医药卫生—肿瘤]